-
Community Update:First Participant Enrolled in the PREVAiLS Phase 3 ALS Study
March 30, 2026 Dear ALS community, We are delighted to share that a new global, pivotal Phase 3 clinical trial, called PREVAiLS, studying the investigational drug pridopidine, has enrolled its… More >>
-
Ferrer and Prilenia Announce First Participant Enrolled inthe “PREVAiLS” Phase 3 Study of Pridopidine in ALS
March 30, 2026 PREVAiLS is a pivotal, global, 500-participant Phase 3 study to evaluate efficacy and safety of pridopidine, an investigational drug, in slowing ALS progression (ALSFRS-R) in early, rapidly… More >>
-
Additional Phase 2 Data of AL-S Pharma Lead Program with AP-101 in ALS
March 19 2026 Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS Results supported by key neuroaxonal injury… More >>
-
Results from the PARADIGM Phase 2b clinical trial of PrimeC in ALS have been published
March 17, 2026 NeuroSense announces that results from the PARADIGM Phase 2b clinical trial of PrimeC in ALS have been published in the prestigious journal JAMA Neurology. The article presents… More >>
-
Argenx statement to the ALS community
February 27, 2026 Update on adimanebart Phase 2a reALISe study in people living with ALS Today, argenx shares an important update on the adimanebart Phase 2a reALISe study in people… More >>
-
VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People with ALS
February 9, 2026 VTx-002 is a first-in-class vectorized antibody to holistically target TDP-43 pathology in ALS recently granted FDA Fast Track Designation for expedited review VectorY Therapeutics, a leader in… More >>
-
VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS
VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the company to proceed with the PIONEER-ALS Phase… More >>
-
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
NeuroSense Therapeutics, a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has completed the review of the Investigational… More >>
